Navigation Links
Plexxikon Inc. to Join Daiichi Sankyo Group
Date:2/28/2011

PARSIPPANY, N.J. and TOKYO, Feb. 28, 2011 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo), today announced that it has concluded an agreement to acquire Plexxikon Inc., a privately held pharmaceutical company based in Berkeley, California with a late-stage oncology product, PLX4032, as well as a promising pipeline and technology platform.

"The acquisition of Plexxikon not only accelerates our entry into the oncology market but strengthens our pipeline and will enable us to achieve our mid- and long-term business objectives of providing world-class, innovative pharmaceuticals in core areas of unmet medical need," said Daiichi Sankyo CEO, Joji Nakayama. "We look forward to working with the esteemed scientists and management team at Plexxikon, who are leaders in the discovery and development of novel small molecule pharmaceuticals to treat human disease."

With the acquisition, Daiichi Sankyo obtains certain co-promotion rights in the United States for PLX4032, which is being jointly developed by Plexxikon and Roche. Interim results from a Phase III trial demonstrated that PLX4032 met co-primary endpoints of overall survival and progression-free survival among patients with previously untreated metastatic melanoma expressing the BRAF mutation.

The acquisition of Plexxikon is consistent with the Daiichi Sankyo commitment to address diverse unmet medical needs, including personalizing medicine to maximize patient benefits. PLX4032 is an elegant example of a targeted therapeutic designed to be administered to patients likely to respond to treatment on the basis of a companion diagnostic test that can detect the presence of a specific genetic mutation.

In addition, the Daiichi Sankyo R&D Division will draw upon the Plexxikon proprietary Scaffold-Based Drug Discovery™ Platform to develop promising new treatments. This unique, systematic, cost-effective platform uses str
'/>"/>

SOURCE Daiichi Sankyo, Co., Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo
2. Daiichi Sankyo, Inc. Acquires First US-Based Packaging and Manufacturing Facility
3. Reportlinker Adds Daiichi Sankyo Co., Ltd: PharmaVitae Profile
4. Daiichi Sankyo Settled Patent Litigation for Evoxac®
5. Accumetrics, Inc., Daiichi Sankyo, Inc. and Eli Lilly and Company Launch Strategic U.S. Collaboration
6. Daiichi Sankyo/Lilly Respond to ACCF/AHA Clinical Alert on Antiplatelet Therapy
7. Daiichi Sankyo Co, Ltd. Joins the National Cherry Blossom Festival in Washington D.C. as Centennial Celebration Committee Co-Chair
8. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
9. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
10. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
11. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014  Medical Science Liaisons play ... key link between the medical device industry and key ... in the coming years as the device industry relies ... According to research by benchmarking firm, Best Practices, LLC, ... an important edge is by harnessing new technology to ...
(Date:12/22/2014)... Tenn. , Dec. 22, 2014   TRU-D ... automated, no-touch UV disinfection robot, announced today that the ... Schedule contract through November 2019.   This ... rapidly engage all levels of government purchasers, including Department ... as well as Homeland Security contacts purchasing solutions for ...
(Date:12/22/2014)... /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII ... and commercializing innovative therapies addressing major unmet medical ... open letter to shareholders from President & CEO, ... Dear RXi Shareholders, In the ... posted on certain social media sites seem to ...
Breaking Medicine Technology:Role of Medical Science Liaisons Evolving in Medical Device Sector 2TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... 2011 StreamVenue Healthcare has partnered its ... Institute for Surgery At Presbyterian Hospital Dallas to ... StreamVenue Healthcare rolled out this year its ... endoscopy technology. The package includes EndoCom hardware; StreamingOR, ...
... Md., April 22, 2011 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... development and commercialization of products for central nervous system disorders, ... of 2011, on Thursday, May 5, 2011, before the market ... disseminated at that time. Mihael H. Polymeropoulos, M.D., ...
Cached Medicine Technology:StreamVenue Healthcare Pacing Future of Endoscopy Technology 2Vanda Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 5, 2011 2
(Date:12/25/2014)... December 26, 2014 The report ... to 2023” focuses on the current treatment landscape, ... the colorectal cancer market. Stivarga is a drug ... or rectal cancer. Boehringer Ingelheim is developing nintedanib ... treatment of refractory CRC in the US, Europe, ...
(Date:12/25/2014)... 26, 2014 Recently, Dylan Queen, a ... excitedly released its collection of discounted prom dresses, most ... a senior spokesman of the company, the promotion is ... promotion is to expand the UK market. , The ... different colors, lengths, and styles: A-line strapless, empire strapless ...
(Date:12/25/2014)... When head lice hits a home or school, parents and ... of it while keeping it from taking over the house ... solution right in their neighborhood: Lice Troopers . Expanding ... spectrum head lice screening and treatment services to families and ... Brickell, Coconut Grove, Kendall, Pinecrest and South Miami. , The ...
(Date:12/25/2014)... -- Among early stage breast cancer patients who undergo ... percent will eventually develop leukemia as a result of ... comes from a review of more than 20,000 breast ... suggests that the risk for developing treatment-related leukemia, though ... "The frequency of bone marrow cancers such as ...
(Date:12/25/2014)... 2014 Plugin creators from Pixel Film ... fully customizable business presentation tool made specifically for ... 5k business tool, users can now display their stats ... Pixel Film Studios. “ProFire 5k gives users a multiple ... professionalism to a presentation” , Pixel Film Studios takes ...
Breaking Medicine News(10 mins):Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... Laboratories, L.P.,today announced that the U.S. Food and Drug ... vitamin D3 product for the,treatment of mild-to-moderate plaque psoriasis ... a chronic skin disorder that affects 2 to 3 ... red, scaly patches of skin and,caused by an abnormally ...
... To mark American Heart,Month, deCODE genetics (Nasdaq: DCGN ... will offer its deCODEme Cardio Scan(TM), the unique new ... of heart,attack, stroke and atrial fibrillation, intracranial and abdominal ... of,$100. , On Thursday, February ...
... 3 NxStage Medical, Inc. (Nasdaq: NXTM ), ... to release its financial results for the fourth quarter and ... 2009 before the opening of the financial markets.NxStage will also ... Thursday, March 12, 2009 to discuss its fourth quarter and ...
... 3 The Albert and Mary Lasker Foundation ... , the immediate past director of the National Institutes of ... Directors."We are delighted that Dr. Zerhouni has agreed to join ... , President of the Lasker Foundation. "The Lasker Foundation is ...
... to Chief Marketing Officer and PACS Industry Veteran ... ManagerWASHINGTON, Feb. 3 Compressus, Inc., leaders in ... team with the promotion of Janine Broda to ... Shawn Gibbons as vice president and general manager ...
... The Female Health Company (NYSE Alternext: FHC) today ... to discuss its operating results for the first quarter ... Tuesday, February 10, 2009. The Company plans to ... day. Shareholders and other interested parties may participate in ...
Cached Medicine News:Health News:Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis 2Health News:Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis 3Health News:Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis 4Health News:deCODEme(TM) Takes on Heart Disease in February 2Health News:deCODEme(TM) Takes on Heart Disease in February 3Health News:deCODEme(TM) Takes on Heart Disease in February 4Health News:deCODEme(TM) Takes on Heart Disease in February 5Health News:NxStage to Report Fourth Quarter and Full Year 2008 Financial Results 2Health News:Lasker Foundation Welcomes Elias Zerhouni to Board of Directors 2Health News:Compressus Bolsters Executive Team to Expand Interoperability Market Pioneered by MEDxConnect(TM) 2Health News:Compressus Bolsters Executive Team to Expand Interoperability Market Pioneered by MEDxConnect(TM) 3Health News:The Female Health Company Schedules First Quarter Conference Call for February 10, 2009 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: